138. Direct and selective nanosensor for amyloid-β oligomers in serum for Alzheimer’s disease diagnosis

RSC Adv., 2025, 15, 16175-16182.

137. CRISPR-Cas12a mediated magnetic aptasensors for direct detection of Brain-derived neurotrophic factor

Microchemical Journal 215 (2025) 114294.

136. Programmable PCR-like Nonenzymatic DNA Molecular Circuit for Split-Free Autocatalytic Amplification

Anal. Chem. 2025, 97, 11847−11855.

135. A Turn-on Fluorescent Immunosensor for Neurodegenerative Disease Related Neurofilament Light Chain Protein

Microchimica Acta (2025) 192:131.

134. The Primary Cilia are Associated with the Axon Initial Segment in Neurons

Adv. Sci. 2025, 12, 2407405.

133. Alterations in the axon initial segment plasticity is involved in early pathogenesis in Alzheimer’s disease

MedComm. 2024;5:e768.

132. The Trend of Nonenzymatic Nucleic Acid Amplification: Strategies and Diagnostic Application

Precis. Chem. 2025, 3, 187−205.

131. A Fe/Zn Dual Single-Atom Nanozyme with High Peroxidase Activities for Detection of Penicillin G

Anal. Chem. 2024, 96, 19248−19257.

130. Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer’s Disease, Resolving Blood–Brain Barrier Crossing Ability

Adv. Sci. 2024, 11, 2403473

129. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy

Molecular Cancer (2024) 23:117

128. Molecular engineering of a theranostic molecule that detects Aβ plaques, inhibits Iowa and Dutch mutation Aβ self-aggregation and promotes lysosomal biogenesis for Alzheimer’s disease

J. Mater. Chem. B, 2024, 12, 7543-7556.

127. Amyloid‑β Guided Responsive Theranostic Fluorescent Probe for Imaging of Endogenous Hydrogen Peroxide in Alzheimer Disease

Sensors and Actuators: B. Chemical 406 (2024) 135452.

126. Programmed aptamer target chain reaction (ATCR) for smart therapeutic inhibitor development

Chemical Engineering Journal 483 (2024) 149228.